Lisata Therapeutics terminates exclusive license for certepetide with Qilu Pharmaceutical

LISATA THERAPEUTICS, INC.

Mutual termination of 2021 License and Collaboration Agreement with Qilu, effective January 23, 2026.
Agreement covered research, development, and commercialization of certepetide (CEND-1) in Greater China.
Lisata was eligible for up to $200M in milestone payments and 10%-15% royalties on net sales.
Termination does not affect obligations accrued prior to termination or certain surviving provisions.
No immediate financial impact disclosed; company loses future milestone/royalty potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.